112677-67-5

Basic information

• Product Name: 3-IMIDAZOL-1-YL-PHENYLAMINE
• Synonyms: 3-IMIDAZOL-1-YL-PHENYLAMINE;3-(1H-imidazol-1-yl)benzenamine;BenzenaMine, 3-(1H-iMidazol-1-yl)-;3-imidazol-1-ylaniline
• CAS NO: 112677-67-5
• Molecular Formula: C₉H₉N₃
• Molecular Weight: 159.191
• Mol File: 112677-67-5.mol
• Article Data: 23

Chemical Properties

• Melting Point: 112-114 °C
• Boiling Point: 373.1±25.0 °C(Predicted)
• Appearance: /
• Density: 1.20±0.1 g/cm3(Predicted)
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• PKA: 5.53±0.10(Predicted)
• CAS DataBase Reference: 3-IMIDAZOL-1-YL-PHENYLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-IMIDAZOL-1-YL-PHENYLAMINE(112677-67-5)
• EPA Substance Registry System: 3-IMIDAZOL-1-YL-PHENYLAMINE(112677-67-5)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 112677-67-5(Hazardous Substances Data)

Usage

Uses

3-(1H-Imidazol-1-yl)aniline is a useful reagent for many copper-catalyzed reactions.

Upstream product

• 23309-09-3 1-(3-nitrophenyl)-1H-imidazole 
• 288-32-4 1H-imidazole 
• 591-19-5 m-Bromoaniline 
• 402-67-5 3-fluoro-1-nitrobenzene 
• 626-01-7 3-Iodoaniline 
• 67-63-0 isopropyl alcohol 
• 30418-59-8 3-Aminophenylboronic acid 
• 585-79-5 m-nitrobromobenzene 

Downstream Products

• 212650-35-6 1-[3-(1H-imidazol-1-yl)phenyl]piperidine-2-acetic acid ethyl ester 
• 112675-52-2 N-<3-(1H-imidazol-1-yl)phenyl>-4-(2-pyridinyl)-2-pyrimidinamine 
• 333793-32-1 N-(3-(imidazol-1-yl)phenyl)-2-phenylthiazole-4-carboxamide 
• 329280-78-6 N-(5-bromo-3-nitropyridin-2-yl)-N-[3-(imidazol-1-yl)phenyl]amine 
• 374555-25-6 (3-imidazol-1ylphenyl)-(5-phenylisoquinolin-1-yl)amine 
• 374555-34-7 (5-bromoisoquinolin-1-yl)-[3-(imidazol-1-yl)phenyl]amine 
• 374555-28-9 [3-(imidazol-1-yl)phenyl]-[5-(thiophen-3-yl)isoquinolin-1-yl]amine 
• 374555-43-8 [3-(imidazol-1-yl)phenyl]-(4-phenylisoquinolin-1-yl)amine 
• 374555-44-9 [3-(imidazol-1-yl)phenyl]-[5-(4-fluorophenyl)isoquinolin-1-yl]amine 
• 374556-13-5 N-(3-(1H-imidazol-1-yl)phenyl)-9-methyl-4,5-dihydro[1]benzoxepino[5,4-c]isoxazol-3-amine 
• 374556-09-9 [3-(imidazol-1-yl)phenyl]-(7-methoxy-5,6-dihydrobenzo[h]quinazolin-2-yl)-amine 

Relevant articles and documents

4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-3,6-DIHYDROPYRIDINE-1-(2H)-CARBOXAMIDE DERIVATIVES AS LIMK AND/OR ROCK KINASES INHIBITORS FOR USE IN THE TREATMENT OF CANCER

The present invention concerns a compound of formula (I), in particular as LIMK and/or ROCK kinases inhibitors. The present invention also concerns these new inhibitors for use for the treatment of a condition selected in the group consisting of: cancers, virion infections, ocular hypertension and glaucoma formation, Neurofibromatosis type 1 and 2, psoriatic lesions, inflammatory diseases and hyperalgesia, central sensitization and chronic pain, reproduction erectile dysfunction, and neuronal diseases. The present description discloses the syntheses and characterisation of exemplary compounds as well as pharmacological data thereof (e.g. pages 32 to 127; examples 1 to 96; families 1 to 8; compounds; biological studies; tables). An exemplary compound is e.g. 4-(5-m ethyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-N-phenyl-3,6-dihydropyridine-1-(2H)-carboxamide (example 1; compound 5).

Fragment-Based Discovery of a Qualified Hit Targeting the Latency-Associated Nuclear Antigen of the Oncogenic Kaposi's Sarcoma-Associated Herpesvirus/Human Herpesvirus 8

The latency-associated nuclear antigen (LANA) is required for latent replication and persistence of Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8. It acts via replicating and tethering the virus episome to the host chromatin and exerts other functions. We conceived a new approach for the discovery of antiviral drugs to inhibit the interaction between LANA and the viral genome. We applied a biophysical screening cascade and identified the first LANA binders from small, structurally diverse compound libraries. Starting from a fragment-sized scaffold, we generated optimized hits via fragment growing using a dedicated fluorescence-polarization-based assay as the structure-activity-relationship driver. We improved compound potency to the double-digit micromolar range. Importantly, we qualified the resulting hit through orthogonal methods employing EMSA, STD-NMR, and MST methodologies. This optimized hit provides an ideal starting point for subsequent hit-to-lead campaigns providing evident target-binding, suitable ligand efficiencies, and favorable physicochemical properties.

L -(-) -Quebrachitol as a Ligand for Selective Copper(0)-Catalyzed N-Arylation of Nitrogen-Containing Heterocycles

l-(-)-Quebrachitol (QCT) has been found as a ligand of copper powder for selective N-arylation of nitrogen-containing heterocycles with aryl halides. Furthermore, another potential catalytic system (copper powder/QCT/t-BuOK) was successfully adapted to unactivated aryl chlorides.